The Thyroid Pharmacist

AUGUST 1, 2025

A practitioner will help assess individual patients to determine if or when breastfeeding is advised. [11]

Health and Personal Care Stores

STAT

JUNE 6, 2023

After finding a “cascade of failures” at a manufacturing plant run by a key chemotherapy supplier, the Food and Drug Administration will not allow the company to resume distribution in the U.S. beyond some   cancer medicines that are in short supply.

Chemotherapy

STAT

AUGUST 1, 2023

Last November, an employee at Intas Pharmaceuticals, which makes several widely used chemotherapies that are in short supply, was seen pouring acetic acid in a trash bin containing documents at a manufacturing facility.

Chemotherapy

pharmaphorum

APRIL 27, 2021

Briefing documents published by the FDA ahead of the meeting suggest that discussion will focus on ongoing trials that may serve as alternative confirmatory studies. A similar trial called Impassion131 of Tecentriq with regular paclitaxel flopped, and even suggested patients treated with paclitaxel alone may have fared better.

Chemotherapy

pharmaphorum

AUGUST 11, 2021

A final appraisal document from the health technology assessment (HTA) agency backs the use of Verzenio (abemaciclib) alongside fulvestrant for the treatment of women with hormone receptor-positive, HER2-negative breast cancer in England and Wales.

Chemotherapy

Pharmaceutical Technology

MARCH 30, 2023

On March 27, MSD announced that the combined use of Keytruda with chemotherapy significantly improved progression-free survival versus the chemotherapy alone, as a first-line therapy for advanced or recurrent endometrial carcinoma. This announcement is not the only recent development for Keytruda.

Chemotherapy

pharmaphorum

MARCH 18, 2021

Keytruda (pembrolizumab) was being reimbursed on an interim basis for advanced or metastatic urothelial carcinoma, following platinum based chemotherapy, by the Cancer Drugs Fund (CDF) until survival data from a larger study emerged.

Chemotherapy

pharmaphorum

FEBRUARY 8, 2022

In briefing documents released by the FDA reviewer, the agency has made it clear that the Chinese clinical results filed in support of the PD-1 inhibitor do not meet the criteria for foreign data fled in support of a marketing application in the US.

Documentation

Pharmaceutical Technology

SEPTEMBER 20, 2022

In a final appraisal document (FAD), the institute recommended the treatment for use in adult patients who have received a minimum of one therapy, only if bendamustine plus rituximab is also appropriate. The post BeiGene gets NICE recommendation for Waldenström’s Macroglobulinemia therapy appeared first on Pharmaceutical Technology.

Chemotherapy

pharmaphorum

NOVEMBER 24, 2022

In final guidance, NICE has backed Opdivo (nivolumab) as a first-line treatment with chemotherapy for previously untreated HER2-negative advanced gastric, gastro-oesophageal junction (GEJ) or oesophageal adenocarcinoma tumours that express PD-L1 with a combined positive score (CPS) of 5 or more. . months compared to 11.4

Chemotherapy

pharmaphorum

OCTOBER 11, 2022

The Scottish Medicines Consortium (SMC) gave the go-ahead to the regimen based on data from the KEYNOTE-775 study , which showed that the duo can increase survival time for patients and may improve quality of life by reducing the symptom burden compared to standard chemotherapy.

Chemotherapy

European Pharmaceutical Review

JULY 4, 2023

Since the first ADC was approved by the EMA in 2012, they have generated a great deal of interest in the oncology field because of their potential to address many of the challenges of traditional chemotherapy options.

Drug Development

pharmaphorum

MARCH 8, 2022

In the study, Trodelvy (sacituzumab govitecan) met its objective of reducing progression-free survival in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment – including endocrine drugs, CDK4/6 inhibitors and two to four lines of chemotherapy.

Chemotherapy

RX Note

JULY 29, 2023

This document is vital for medicolegal purposes. ophthalmic gel forming solution - Infantile haemangioma, superficial Vancomycin injection (for oral use) - Treatment of Clostridium Difficile associated diarrhoea Examples of off-label dose Antihistamine - Updosing up to fourfold. Copy of the consent form must be kept in the patients' record.

Labelling

RX Note

JUNE 5, 2023

Personal Protective Equipment Wearing chemotherapy gloves ( ASTM D6978-tested gloves ) Use powder-free gloves because the powder can contaminate the work area and might adsorb and retain hazardous drugs. Oral hazardous drugs No crushing or compounding may be done in an unprotected environment.

Compounding

Pharmaceutical Technology

NOVEMBER 4, 2022

Marian McNeil says she became interested in precision medicine when working for a company developing oral cancer treatments that would avoid the need for intravenous chemotherapy. To learn more about how digital health is transforming health services in Scotland, download the document on this page. It's an exciting place to be.”.

Diabetes

pharmaphorum

JANUARY 15, 2021

GSK estimates that around 3,000 people could benefit annually from the decision covering advanced high-grade epithelial ovarian cancer, fallopian tube or primary peritoneal cancer, who have completed and shown a response to platinum-based chemotherapy. Zejula pills are taken three times daily.

Chemotherapy

pharmaphorum

SEPTEMBER 13, 2022

The first well-documented case of multiple myeloma was reported in 1844 by renowned British surgeon Samuel Solly. 1942 – Chemotherapy moves from trenches to treatment . Before the birth of bone marrow transplants, patients were often treated using chemotherapy, which could be used to kill cancer cells.

Chemotherapy

pharmaphorum

SEPTEMBER 17, 2021

Keytruda (pembrolizumab) has been given the green light for use alongside platinum- and fluoropyrimidine-based chemotherapy in patients with locally advanced or metastatic oesophageal cancer that cannot be treated with surgery. At the moment they are generally treated with palliative chemo.

Chemotherapy

pharmaphorum

MARCH 18, 2021

AstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS England patients with chronic lymphocytic leukaemia (CLL) who can’t be treated with first-line chemotherapy. The decision is at odds with the situation in Scotland, where Nilemdo was turned down in December.

Hospitals

RX Note

JUNE 3, 2023

What are the prechemotherapy checks before initiating chemotherapy. For the condition below, list down 3 chemotherapy regimens (including dosing and interval) Acute myeloid leukaemia Breast cancer Colorectal cancer Hodgkin's lymphoma Non-Hodgkin's lymphoma Multiple myeloma Ovarian cancer State 5 examples of targeted therapies of cancer.

Health and Personal Care Stores

LifeProNow

APRIL 19, 2023

The primary endpoint evaluated in this study is progression-free survival, defined as time from randomization to the first documentation of progressive disease or death due to any cause, whichever occurs first. Key secondary endpoints include overall response rate and overall survival.

Adverse Reactions

RX Note

FEBRUARY 23, 2023

Drug Complaint - Actions to be taken Drug Recall - A brief overview Sterile and Nonsterile Manufacturing & Prepacking Extemporaneous Formulation - Discussing on references, vehicle in extemporaneous formulations and alcohol in compounding Extemporaneous Preparation with Unknown Stability - Some recommendations Extemporaneous Compounding - Discussing (..)

HIV Treatment and Prevention Agents